Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study | Zendy

M. Tobias Heinrichs | Zendy; Sergo Vashakidze | Zendy; Ketino Nikolaishvili | Zendy; Irina Sabulua | Zendy; Nestani Tukvadze | Zendy; Nino Bablishvili | Zendy; Shota Gogishvili | Zendy; Brent P. Little | Zendy; Adam Bernheim | Zendy; Jeannette Guarner | Zendy; Charles A. Peloquin | Zendy; Henry M. Blumberg | Zendy; Hartmut Derendorf | Zendy; Russell R. Kempker | Zendy

Open Access

Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study

Author(s) -

M. Tobias Heinrichs,

Sergo Vashakidze,

Ketino Nikolaishvili,

Irina Sabulua,

Nestani Tukvadze,

Nino Bablishvili,

Shota Gogishvili,

Brent P. Little,

Adam Bernheim,

Jeannette Guarner,

Charles A. Peloquin,

Henry M. Blumberg,

Hartmut Derendorf,

Russell R. Kempker

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx421

Subject(s) - moxifloxacin , pharmacokinetics , medicine , cmax , microdialysis , lung , dosing , drug , in vivo , pharmacodynamics , antibiotics , surgery , pharmacology , gastroenterology , urology , chemistry , biology , microbiology and biotechnology , central nervous system , biochemistry

Moxifloxacin is a second-line anti-TB drug that is useful in the treatment of drug-resistant TB. However, little is known about its target site pharmacokinetics. Lower drug concentrations at the infection site (i.e. in severe lung lesions including cavitary lesions) may lead to development and amplification of drug resistance. Improved knowledge regarding tissue penetration of anti-TB drugs will help guide drug development and optimize drug dosing.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research